2021
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease
Authors:
Picard, C., Nilsson, N., Labonté, A., Auld, D., Rosa-Neto, P., Alzheimer's Disease Neuroimaging Initiative, Ashton, N. J., Zetterberg, H., Blennow, K., Breitner, J. C. B., Villeneuve, S., Poirier, J., & PREVENT-AD research group
Journal:
Alzheimer's & Dementia
Abstract
Introduction: We examine the role of brain apolipoprotein B (apoB) as a putative marker of early tau pathology and cognitive decline.
Methods: Cerebrospinal fluid (CSF) samples from cognitively normal and Alzheimer’s disease (AD) participants were collected to measure protein levels of apoB and AD biomarkers amyloid beta (Aβ), t-tau and p-tau, as well as synaptic markers GAP43, SYNAPTOTAGMIN-1, synaptosome associated protein 25 (SNAP-25), and NEUROGRANIN. CSF apoB levels were contrasted with positron emission tomography (PET) scan measures of Aβ (18F-NAV4694) and Tau (flortaucipir) along with cognitive assessment alterations over 6 to 8 years.
Results: CSF apoB levels were elevated in AD participants and correlated with t-tau, p-tau, and the four synaptic markers in pre-symptomatic individuals. In the latter, CSF apoB levels correlated with PET flortaucipir-binding in entorhinal, parahippocampal, and fusiform regions. Baseline CSF apoB levels were associated with longitudinal visuospatial cognitive decline.
Discussion: CSF apoB markedly associates with early tau dysregulation in asymptomatic subjects and identifies at-risk individuals predisposed to develop visuospatial cognitive decline over time.
Share
Receive the
latest news
Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.
